Cerus (NASDAQ:CERS - Get Free Report) posted its quarterly earnings results on Thursday. The biotechnology company reported ($0.01) earnings per share for the quarter, hitting the consensus estimate of ($0.01), Zacks reports. The company had revenue of $50.81 million for the quarter, compared to the consensus estimate of $50.81 million. Cerus had a negative return on equity of 40.55% and a negative net margin of 11.60%.
Cerus Stock Down 5.2 %
NASDAQ CERS traded down $0.09 during mid-day trading on Friday, reaching $1.65. The stock had a trading volume of 3,456,830 shares, compared to its average volume of 1,402,488. The stock has a market cap of $306.42 million, a PE ratio of -15.00 and a beta of 1.29. Cerus has a 1 year low of $1.38 and a 1 year high of $2.59. The company has a debt-to-equity ratio of 1.19, a current ratio of 2.59 and a quick ratio of 1.92. The company has a fifty day moving average price of $1.74 and a 200 day moving average price of $1.84.
Analyst Ratings Changes
Separately, Cantor Fitzgerald reissued an "overweight" rating and issued a $4.00 target price on shares of Cerus in a research note on Friday.
View Our Latest Stock Report on CERS
Insider Buying and Selling at Cerus
In other news, Director Eric Bjerkholt sold 20,000 shares of the firm's stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $1.78, for a total transaction of $35,600.00. Following the sale, the director now owns 162,133 shares of the company's stock, valued at $288,596.74. This trade represents a 10.98 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 3.40% of the company's stock.
Cerus Company Profile
(
Get Free Report)
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Recommended Stories
Before you consider Cerus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cerus wasn't on the list.
While Cerus currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
